Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ruthenium complexes as anticancer agents.

Irena Kostova1

  • 1Department of Chemistry, Faculty of Pharmacy, Medical University, 2 Dunav St., Sofia 1000, Bulgaria. irenakostova@yahoo.com

Current Medicinal Chemistry
|April 14, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heterometallic Multinuclear Ruthenium Complexes as Cytotoxic Agents.

Biomedicines·2026
Same author

Parabiotics as Next-Generation Microbiome Therapeutics: Insights into Mechanisms, Evidence, and Therapeutic Potential.

Current microbiology·2026
Same author

Retraction Notice: Titanium and Vanadium Complexes as Anticancer Agents.

Anti-cancer agents in medicinal chemistry·2026
Same author

Recent Advances in Anticancer Research of Osmium and Rhodium Complexes.

Medicinal chemistry (Shariqah (United Arab Emirates))·2025
Same author

Homometallic Polynuclear Rhodium Complexes in Anticancer Drug Development.

Mini reviews in medicinal chemistry·2025
Same author

Cytotoxic Organometallic Iridium(III) Complexes.

Molecules (Basel, Switzerland)·2025
Same journal

LncRNA signature associated with amino acid metabolism: A novel prognostic tool for Clear Cell Renal Cell Carcinoma.

Current medicinal chemistry·2026
Same journal

HRI Kinase Modulation by BTdCPU as a Therapeutic Strategy for Bortezomib Resistance in Prostate Cancer.

Current medicinal chemistry·2026
Same journal

EGFR Dysregulation in Cancer: From Molecular Mechanisms and Key Mutations to Evolving TKI Strategies and Resistance Mitigation.

Current medicinal chemistry·2026
Same journal

DHRS2 as a Novel Thalidomide Target Regulating Mitophagy and Inflammation in Head and Neck Squamous Cell Carcinoma.

Current medicinal chemistry·2026
Same journal

Synthetic AtMP2 from Anabas testudineus: Comprehensive ADMET and In Vivo Toxicity Assessment to Enable Future Therapeutic Development.

Current medicinal chemistry·2026
Same journal

Screening of Medicinal and Edible Homology Substances for Diabetic Kidney Disease Based on GraphBAN.

Current medicinal chemistry·2026
See all related articles

Ruthenium complexes show promise as novel anticancer agents, offering potential against resistant tumors and reduced toxicity compared to traditional therapies. Their ability to target DNA and exhibit antimetastatic properties warrants further investigation in cancer treatment.

Area of Science:

  • Medicinal Chemistry
  • Inorganic Chemistry
  • Oncology

Background:

  • Cancer remains a leading cause of death globally, with current treatments like chemotherapy facing limitations due to side effects and drug resistance.
  • The development of novel chemotherapeutic agents is crucial, especially for disseminated cancers where curative therapies are lacking.
  • While platinum-based drugs like cisplatin have been effective, there is a need for agents with improved efficacy and reduced toxicity.

Purpose of the Study:

  • To review the advancements in medicinal chemistry concerning ruthenium (Ru) complexes as anticancer agents.
  • To discuss the DNA binding modes and development status of Ru(II) and Ru(III) complexes.
  • To critically examine the past and present research on ruthenium compounds for their potential role in cancer therapy.

Related Experiment Videos

Main Methods:

  • Literature review of scientific publications on ruthenium complexes and their anticancer properties.
  • Analysis of studies focusing on the synthesis, characterization, and biological evaluation of Ru(II) and Ru(III) complexes.
  • Examination of research detailing DNA binding interactions and antimetastatic effects of ruthenium compounds.

Main Results:

  • Ruthenium complexes have demonstrated significant antitumor and antimetastatic properties in preclinical animal models.
  • Certain Ru(II) and Ru(III) complexes exhibit comparable or enhanced activity against cisplatin-resistant tumors.
  • These compounds show potential for lower systemic toxicity compared to conventional chemotherapeutic agents.
  • Ruthenium compounds effectively penetrate tumor cells and bind to DNA, suggesting a key mechanism of action.

Conclusions:

  • Ruthenium complexes represent a promising class of inorganic compounds for cancer therapy, offering selective antimetastatic properties and reduced toxicity.
  • Further research and clinical development of Ru(II) and Ru(III) complexes are warranted to explore their full therapeutic potential.
  • Ruthenium-based drugs could offer a valuable alternative or adjunct to existing cancer treatments, particularly for resistant malignancies.